Shanghai Zerun Biotechnology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2003-05-07
- Employees
- -
- Market Cap
- -
- Website
- http://www.zerunbio.com
Clinical Trials
12
Active:6
Completed:5
Trial Phases
3 Phases
Phase 1:5
Phase 2:3
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (45.5%)Phase 2
3 (27.3%)Phase 3
3 (27.3%)Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
Active, not recruiting
- Conditions
- Cervical CancerVulvar CancerVaginal CancerCIN - Cervical Intraepithelial NeoplasiaHuman Papillomavirus Infection
- Interventions
- Biological: HPV-16/18 vaccineBiological: Placebo
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 5372
- Registration Number
- NCT06776055
- Locations
- 🇨🇳
Lingchuan Center for Disease Control and Prevention, Lingchuan, Guangxi, China
🇨🇳Quanzhou Center for Disease Control and Prevention, Quanzhou, Guangxi, China
🇨🇳Xing'an Center for Disease Control and Prevention, Xing'an, Guangxi, China
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Phase 3
Active, not recruiting
- Conditions
- Genital WartVINCINPapillomavirus InfectionsCervical Cancer
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 1200
- Registration Number
- NCT05580341
- Locations
- 🇨🇳
GuangXi Center for Diseases Control and Prevention, Nanning, Guangxi, China
Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.
Phase 1
Active, not recruiting
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT05490108
- Locations
- 🇲🇱
Center for Vaccine Development-Mali, Bamako, Mali
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 1
Active, not recruiting
- Conditions
- COVID-19
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 84
- Registration Number
- NCT05313022
- Locations
- 🇨🇳
Clinical Trial Institution for Anning First Hospital, Kunming, Yunan, China
Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 2
Active, not recruiting
- Conditions
- COVID-19
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 528
- Registration Number
- NCT04990544
- Locations
- 🇨🇳
Xiangcheng Center for Disease Control and Prevention, Xuchang, China
- Prev
- 1
- 2
- 3
- Next
News
No news found